The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-23 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
The International System of Units (SI) unit of radioactive activity is the becquerel (Bq), named in honor of the scientist Henri Becquerel. One Bq is defined as one transformation (or decay or disintegration) per second. An older unit of radioactivity is the curie, Ci, which was originally defined as "the quantity or mass of radium emanation in equilibrium with one gram of radium (element)". Today, the curie is defined as 3.7×1010 disintegrations per second, so that 1 curie (Ci) = 3.7×1010 Bq. For radiological protection purposes, although the United States Nuclear Regulatory Commission permits the use of the unit curie alongside SI units, the European Union European units of measurement directives required that its use for "public health ... purposes" be phased out by 31 December 1985. Absorbed dose is measured in grays (Gy), while equivalent and effective doses are expressed in sieverts (Sv).
(CH2CH2)O → •CH2CH2O• → CH2O + CH2: When carrying the thermal decomposition of ethylene oxide in the presence of transition metal compounds as catalysts, it is possible not only to reduce its temperature, but also to have ethyl as the main product, that is to reverse the ethylene oxide synthesis reaction.
== Mechanism == As previously mentioned, BCKDC's primary function in mammals is to catalyze an irreversible step in the catabolism of branched-chain amino acids. However BCKDC has a relatively broad specificity, also oxidizing 4-methylthio-2-oxobutyrate and 2-oxobutyrate at comparable rates and with similar Km values as for its branched-chain amino acid substrates. The BCKDC will also oxidize pyruvate, but at such a slow rate this side reaction has very little physiological significance. The reaction mechanism is as follows. Please note that any of several branched-chain α-ketoacids could have been used as a starting material; for this example, α-ketoisovalerate was arbitrarily chosen as the BCKDC substrate.
The other feature was a new cooling arrangement positioned aft (single ducted water and oil radiators assembly) that reduced the fuselage drag and effects on the wing. Later, after much development, they discovered that the cooling assembly could take advantage of the Meredith effect, in which heated air exited the radiator with a slight amount of jet thrust. Because NAA lacked a suitable wind tunnel to test this feature, it used the GALCIT 3.0 m (10 ft) wind tunnel at the California Institute of Technology. This led to some controversy over whether the Mustang's cooling system aerodynamics were developed by NAA's engineer Schmued or by Curtiss, as NAA had purchased the complete set of P-40 wind tunnel data and flight test reports. The NA-73X was also one of the first aircraft to have a fuselage lofted mathematically using conic sections; this resulted in smooth, low-drag surfaces. To aid production, the airframe was divided into five main sections—forward, center, rear fuselage, and two wing halves—all of which were fitted with wiring and piping before being joined. The prototype NA-73X was rolled out in September 1940, just 102 days after the order had been placed; it first flew on 26 October 1940, 149 days into the contract, an uncommonly short development period even during the war. With test pilot Vance Breese at the controls, the prototype handled well and accommodated an impressive fuel load. The aircraft's three-section, semi-monocoque fuselage was constructed entirely of 24S aluminum alloy (a type of Duralumin) to save weight.
== External links == Gerngross TU, Slater SC (August 2000). "How green are green plastics?". Sci. Am. 283 (2): 37–41. Bibcode:2000SciAm.283b..36G. doi:10.1038/scientificamerican0800-36. PMID 10914397. Plastics from plants called costly (CNN) Tillman Gerngross Faculty Page at Dartmouth About Adimab LLC.
Sources: en.wikipedia.org
== Research == Due to its high biocompatibility, bioactivity, osteoconductive and/or osteoinductive capacity, nontoxicity, nonimmunogenic properties, and noninflammatory behavior, hydroxyapatite is available and used as a bone filler and as coatings on prostheses. Designing bone scaffolds with a higher capability of promoting bone regeneration is a topical research subject. Composite 3D scaffolds for bone tissue engineering based on nano-hydroxyapatite and poly-ε-caprolactone were designed. The 3D composite scaffolds showed good cytocompatibility and osteogenic potential, which is specifically recommended in applications when faster mineralization is needed, such as osteoporosis treatment.
== Cast == Johnathon Schaech as Justin Wise Sarah Lancaster as Elli Wise Taegen Burns as Maddie Wise A Martinez as Connor McGrath Avianna Mynhier as Maxine 'Maxx' Covington Greg Perrow as Deputy R.P. Ericsson Tom Proctor as Jeremiah Wade Lev Cameron as Blade Wade Odessa Feaster as Mayor Brady Grayson Russell as Dwayne Dixon Burgess Jenkins as Ryan Lucas
Even though PMTX has no structural homology with other toxins acting on sodium channels, such as sea anemone toxins or scorpion toxins, some parts of these toxins show similar structures to interact with the receptor site of the sodium channels.
== Design == Silicone gel sheets are usually made of medical silicone polymers such as polysiloxane and polydimethylsiloxane, along with silicon dioxide and volatile components. The long-chain silicone polymers form cross-linking with silicon dioxide and spread as a thin sheet. They are either flesh color (most common) or clear and come as either a single large rectangle sheet or a roll. Available size varies with brands.
Alcohol: It has been reported that combined use of alcohol and kava extract can have additive sedative effects. Kava has been shown to create additive cognitive impairments when taken with alcohol, compared to taking placebo and alcohol alone. Anxiolytics (CNS depressants such as benzodiazepines and barbiturates): Kava may have potential additive CNS depressant effects (such as sedation and anxiolytic effects) with benzodiazepines and barbiturates. Kava taken in combination with alprazolam can cause a semicomatose state in humans. Dopamine agonist such as levodopa: One of levodopa's chronic side effects in Parkinson's patients is the "on-off phenomenon" of motor fluctuations - periods of oscillations between "on", where the patient experiences symptomatic relief, and "off", where the therapeutic effect wears off early. When levodopa and kava are taken together, it has been shown that there is an increased frequency of this "on-off phenomenon".
Sources: en.wikipedia.org
== "The Genesis of the 'Final Solution’ from the Spirit of Science" == Peukert is perhaps best known for his 1989 essay “The Genesis of the 'Final Solution’ from the Spirit of Science” from his book Max Webers Diagnose der Moderne. Peukert began his essay with an attack on the conservative side in the Historikerstreit, stating that the obsession of Ernst Nolte with proving that Hitler had been somehow forced into committing genocide by the fear of the Soviet Union was an apologistic argument meant to diminish the horror of Auschwitz. Peukert further noted that on the origins of the Holocaust question that the internationalist argument that the "Final Solution to the Jewish Question" was all part of a master plan carried out by Hitler and a few of his followers is not longer accepted by most historians with the "Final Solution" being seen instead as the product of several processes coming together at the same time. Peukert wrote that the Shoah was not the result solely of anti-Semitism, but was instead the a product of the "cumulative radicalization" in which "numerous smaller currents" fed into the "broad current" that led to genocide. Peukert wrote the Holocaust was a product of:
=== Paleontology === Although the word dinosaur can be used pejoratively to describe something that is becoming obsolete due to failing to adapt to changing conditions, non-avian dinosaurs did not become extinct due to being generally maladapted or unable to cope with normal climatic change, a view found in many older textbooks. Moreover, not all dinosaurs are extinct (see below). Dinosaurs are not extinct, as birds are classified within the theropod dinosaur lineage. The word dinosaur is commonly used to refer only to non-avian dinosaurs, reflecting an outdated conception of the ancestry of avian dinosaurs, the birds. The evolutionary origin of birds was an open question in paleontology for over a century, but the modern scientific consensus is that birds evolved from small feathered theropods in the Jurassic. Not all dinosaur lineages were cut short at the end of the Cretaceous during the Cretaceous–Paleogene extinction event, and over 11,000 species of avian theropods survive as part of the modern fauna. Dinosaurs, pterosaurs, and ichthyosaurs were not cold-blooded. Dinosaur thermoregulation is a topic of ongoing study. However, their high growth rates and the presence of dinosaur fossils in cold polar climates make cold-bloodedness implausible. Pterosaurs are inferred to be warm-blooded because they had a hair-like body covering, a trait absent in modern cold-blooded animals. Estimates of ichthyosaur body temperature are similar to marine mammals in every climate.
== Etymology == The term is derived from integumentum, which is Latin for "a covering". In a transferred, or figurative sense, it could mean a cloak or a disguise. In English, "integument" is a fairly modern word, its origin having been traced back to the early seventeenth century; and refers to a material or layer with which anything is enclosed, clothed, or covered in the sense of "clad" or "coated", as with a skin or husk.
The catalytic activity of the resulting MOF was examined by carrying out alcohol oxidation with H2O2 as the oxidant. It also catalyzed the oxidation of primary alcohol, secondary alcohol and benzyl alcohols with high selectivity. Hill et al. have demonstrated the sulfoxidation of thioethers using a MOF based on vanadium-oxo cluster V6O13 building units. A MOF loaded with propylene oxide can act as a catalyst, converting CO2 into cyclic carbonates (ring-shaped molecules with many applications). They can also remove carbon from biogas. This MOF is based on lanthanides, which provide chemical stability. This is especially important because the gases the MOF will be exposed to are hot, high in humidity, and acidic. Triaminoguanidinium-based POFs and Zn/POFs are new multifunctional materials for environmental remediation and biomedical applications.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.